Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 11:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 983 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Coronary Syndrome Clear all
Withdrawn No phase listed Observational

Hispanics With Metabolic Syndrome and Non-ischemic Heart Failure

NCT00804882
View directory record Official record
Conditions
Metabolic Syndrome, Heart Failure
Interventions
Not listed
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 59 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 2, 2026, 11:19 AM EDT
Completed Phase 3 Interventional Results available

Cardiovascular Inflammation Reduction Trial

NCT01594333
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Methotrexate, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
4,786 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
404
States / cities
Birmingham, Alabama • Fort Payne, Alabama • Guntersville, Alabama + 296 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 2, 2026, 11:19 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome

NCT07273838
View directory record Official record
Conditions
Heart Failure, Acute Kidney Injury
Interventions
Dapagliflozin 10mg Tab, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 85 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 2, 2026, 11:19 AM EDT
Not listed Phase 4 Interventional

Novel Form of Acquired Long QT Syndrome

NCT04169100
View directory record Official record
Conditions
Long QT Syndrome, Connective Tissue Diseases, Rheumatoid Arthritis
Interventions
Prednisone
Drug
Lead sponsor
Narrows Institute for Biomedical Research
Other
Eligibility
18 Years to 89 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 2, 2026, 11:19 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Cardiovascular Health Improvement Project

NCT02306200
View directory record Official record
Conditions
Aortic Aneurysm, Aortic Dissection, Bicuspid Aortic Valve (BAV), Heart Failure, Cardiovascular Diseases
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2053
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 2, 2026, 11:19 AM EDT
Recruiting Not applicable Interventional

Heart Coherence Training on Vascular Ehlers-Danlos Syndrome Patients

NCT05994664
View directory record Official record
Conditions
Vascular Ehlers-Danlos Syndrome
Interventions
Heartmath Intervention, Control Group
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 2, 2026, 11:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

3D Modalities for Medical Student Education of Congenital Heart Disease

NCT07295730
View directory record Official record
Conditions
Tetralogy of Fallot (TOF), Hypoplastic Left Heart Syndrome (HLHS)
Interventions
3D-printed heart models and augmented reality
Other
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 2, 2026, 11:19 AM EDT
Completed Not applicable Interventional Results available

Exercise and Pioglitazone for HIV-Metabolic Syndromes

NCT00639457
View directory record Official record
Conditions
HIV Infections, Type 2 Diabetes, Obesity, HIV, AIDS, Cardiovascular Disease, Lipodystrophy
Interventions
Pioglitazone, Exercise training
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Oct 2, 2026, 11:19 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Observational Study to Evaluate Peripheral IntraVenous Analysis (PIVA) in Euvolemic, Hypovolemic, and Hypervolemic Emergency Department Patients

NCT03736421
View directory record Official record
Conditions
Infection, Hypervolemia, Hypovolemia, Septic Shock, Acute Heart Failure, Congestive Heart Failure
Interventions
Peripheral Intravenous Analysis (PIVA), Non-invasive fluid response measure, Passive leg raise (PLR)
Procedure · Diagnostic Test
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 2, 2026, 11:19 AM EDT
Terminated Phase 2 Interventional

Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome

NCT00351221
View directory record Official record
Conditions
Noonan Syndrome
Interventions
rhIGF-1/rhIGFBP-3
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
2 Years to 16 Years
Enrollment
24 participants
U.S. locations
2
States / cities
New Hyde Park, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2007 · Synced Oct 2, 2026, 11:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Turner Syndrome: Genotype and Phenotype

NCT00006334
View directory record Official record
Conditions
Turner's Syndrome
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
10 Years and older
Enrollment
1,017 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 2, 2026, 11:19 AM EDT
Terminated Phase 1 Interventional

Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome

NCT02398604
View directory record Official record
Conditions
Hypoplastic Left Heart Syndrome
Interventions
Allo-hMSCs, Placebo
Drug
Lead sponsor
Longeveron Inc.
Industry
Eligibility
Up to 30 Days
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 2, 2026, 11:19 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE)

NCT05149898
View directory record Official record
Conditions
22Q11.2 Deletion Syndrome
Interventions
ZYN002
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
4 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 2, 2026, 11:19 AM EDT
Active, not recruiting Early Phase 1 Interventional

Modafinil and Cognitive Function in POTS

NCT01988883
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
Placebo, Modafinil, Propranolol
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 2, 2026, 11:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Predictive Genetic Risk Assessment Trial

NCT00782366
View directory record Official record
Conditions
Colon Cancer, Lung Cancer, Atrial Fibrillation, Diabetes Type 2, Obesity, Breast Cancer, Graves Disease, Osteoarthritis, Celiac Disease, Myocardial Infarction, Prostate Cancer
Interventions
SNP analysis
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Oct 2, 2026, 11:19 AM EDT
Completed Phase 3 Interventional

Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction

NCT00714961
View directory record Official record
Conditions
Acute Coronary Syndromes
Interventions
Clopidogrel (SR25990), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
3,491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 2, 2026, 11:19 AM EDT
Completed Phase 2 Interventional

Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial

NCT01201837
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Placebo, CER-001
Drug
Lead sponsor
Cerenis Therapeutics, SA
Industry
Eligibility
Up to 75 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
24
States / cities
Huntsville, Alabama • Phoenix, Arizona • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Oct 2, 2026, 11:19 AM EDT
Not yet recruiting Not applicable Interventional

Self-directed Mobile Mindfulness to Address ICU Survivors' Psychological Distress

NCT07634419
View directory record Official record
Conditions
Critical Illness, Heart Failure, Sepsis, Ards, Pneumonia, Trauma Injury
Interventions
Lift mobile mindfulness, Enlighten Recovery education program
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
3
States / cities
Los Angeles, California • Durham, North Carolina • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 2, 2026, 11:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Benefits of Eggs in Combination With a Plant-based Diet

NCT04234334
View directory record Official record
Conditions
Coronary Artery Disease, Diabetes, Metabolic Syndrome
Interventions
Consume 2 eggs with spinach per day, Egg Subsitute with spinach per day
Other
Lead sponsor
University of Connecticut
Other
Eligibility
35 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 2, 2026, 11:19 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions

NCT02895906
View directory record Official record
Conditions
22q11.2 Deletion Syndrome
Interventions
NFC-1
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
12 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 2, 2026, 11:19 AM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 2, 2026, 11:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin

NCT01756495
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Losmapimod, Moxifloxacin, Losmapimod matched Placebo, Moxifloxacin Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 2, 2026, 11:19 AM EDT
Completed Phase 4 Interventional

Prevention of Atrial Arrhythmia in Patients Without Atrioventricular (AV) Conduction Disease

NCT01170611
View directory record Official record
Conditions
Sinus Node Dysfunction, Brady Tachy Syndrome
Interventions
PACEMAKER SYMPHONY 2550
Device
Lead sponsor
LivaNova
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
10
States / cities
Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2010 · Synced Oct 2, 2026, 11:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fetal Intervention for Aortic Stenosis and Evolving Hypoplastic Left Heart Syndrome

NCT01736956
View directory record Official record
Conditions
Aortic Stenosis, Hypoplastic Left Heart Syndrome
Interventions
Fetal Aortic Valvuloplasty
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 2, 2026, 11:19 AM EDT